Clinical Trial Update: EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial exploring a combination of EGFR-TKIs with anlotinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• EGFR-TKIs

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: EGFR Gene Mutation | Phase 2 | Status: UNKNOWN